Daniel Boffa, MD, discusses the choice between definitive surgery vs definitive chemoradiotherapy for patients with early-stage esophageal carcinoma.
Daniel Boffa, MD
Advertisement
Daniel Boffa, MD, is a professor of thoracic surgery, division chief of Thoracic Surgery, and the clinical director of the Center for Thoracic Cancers at Yale School of Medicine.
Articles by Daniel Boffa, MD
Advertisement
Latest Updated Articles
Dr Boffa on Factors Informing Early-Stage Esophageal Cancer ManagementPublished: April 29th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5